Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases
- 5 December 2019
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (2) , 328
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEuropean Heart Journal, 2019
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes MellitusCirculation, 2019
- Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017Diabetes, Obesity and Metabolism, 2018
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998